Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 22
1984 57
1985 67
1986 95
1987 78
1988 126
1989 174
1990 207
1991 248
1992 306
1993 273
1994 372
1995 507
1996 494
1997 472
1998 512
1999 564
2000 483
2001 521
2002 555
2003 517
2004 458
2005 609
2006 464
2007 365
2008 350
2009 353
2010 417
2011 380
2012 394
2013 376
2014 388
2015 446
2016 406
2017 376
2018 356
2019 355
2020 407
2021 391
2022 402
2023 357
2024 145

Text availability

Article attribute

Article type

Publication date

Search Results

13,984 results

Results by year

Filters applied: . Clear all
Page 1
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E, Toumi H. Lespessailles E, et al. Int J Mol Sci. 2022 Sep 14;23(18):10733. doi: 10.3390/ijms231810733. Int J Mol Sci. 2022. PMID: 36142643 Free PMC article. Review.
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). ...
As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pan …
An update on drug-drug interactions associated with proton pump inhibitors.
Ben Ghezala I, Luu M, Bardou M. Ben Ghezala I, et al. Expert Opin Drug Metab Toxicol. 2022 May;18(5):337-346. doi: 10.1080/17425255.2022.2098107. Epub 2022 Jul 11. Expert Opin Drug Metab Toxicol. 2022. PMID: 35787720 Review.
Interestingly, not all PPIs have the same pharmacokinetic and pharmacodynamic profile, with some having a strong potential to inhibit CYP2C19, such as omeprazole, esomeprazole, and lansoprazole, while others, pantoprazole, rabeprazole, and dexlansoprazole, are weak …
Interestingly, not all PPIs have the same pharmacokinetic and pharmacodynamic profile, with some having a strong potential to inhibit CYP2C1 …
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, Zhao F, Wang S. Qi Q, et al. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10. doi: 10.5414/CP202396. Int J Clin Pharmacol Ther. 2015. PMID: 26329348 Review.
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD). ...A significant difference between esomeprazole 20 mg and omeprazole 40 mg (RR=0.68, 95% CI [0.47, 0 …
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophagea …
Reply.
Nieves JW, Perez MC, Metz DC, Hansen KE. Nieves JW, et al. Gastroenterology. 2019 Aug;157(2):586. doi: 10.1053/j.gastro.2019.06.006. Epub 2019 Jun 13. Gastroenterology. 2019. PMID: 31260666 No abstract available.
Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.
Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Lee KN, et al. World J Gastroenterol. 2022 Nov 28;28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294. World J Gastroenterol. 2022. PMID: 36504556 Free PMC article. Clinical Trial.
Fexuprazan's suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent manner. AIM: To compare fexuprazan to esomeprazole and establish its efficacy and safety in patients with erosive esophagitis (EE). ...RESULTS: Of the 263 randomized …
Fexuprazan's suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent manner. AIM: To compare fexupraz …
Esomeprazole.
Spencer CM, Faulds D. Spencer CM, et al. Drugs. 2000 Aug;60(2):321-9; discussion 330-1. doi: 10.2165/00003495-200060020-00006. Drugs. 2000. PMID: 10983736 Review.
Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer. ...Esomeprazole-based triple therapy for 7 days was as effective for eradication of Helicobacter pylori as longer o …
Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a …
Introduction: Biocatalysis in Industry.
Hughes G, Lewis JC. Hughes G, et al. Chem Rev. 2018 Jan 10;118(1):1-3. doi: 10.1021/acs.chemrev.7b00741. Chem Rev. 2018. PMID: 29316793 No abstract available.
Introduction.
Illueca M. Illueca M. J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S1. doi: 10.1097/01.mpg.0000466914.65742.da. J Pediatr Gastroenterol Nutr. 2015. PMID: 26422092 No abstract available.
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P Jr, Katz PO, Chen Y, Sostek M. Miner P Jr, et al. Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. ...On day 5, intragastric pH was maintained above 4.0 for a mean of 14.0 h with esomeprazole …
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, om …
Reply.
Cluver C, Hannan N, Tong S. Cluver C, et al. Am J Obstet Gynecol. 2019 Feb;220(2):207. doi: 10.1016/j.ajog.2018.10.009. Epub 2018 Oct 10. Am J Obstet Gynecol. 2019. PMID: 30315783 No abstract available.
13,984 results
You have reached the last available page of results. Please see the User Guide for more information.